The proliferation of meta-analyses (with one of which the author has been associated 1 ) of different blood pressure (BP) lowering strategies and cardiovascular outcome is an indication of the fact that no single trial to date has satisfactorily or conclusively answered the question of which drug or drug regimen confers the greatest protection against stroke, myocardial infarction (MI) and other cardiovascular endpoints in the hypertensive population.
The proliferation of meta-analyses (with one of which the author has been associated 1 ) of different blood pressure (BP) lowering strategies and cardiovascular outcome is an indication of the fact that no single trial to date has satisfactorily or conclusively answered the question of which drug or drug regimen confers the greatest protection against stroke, myocardial infarction (MI) and other cardiovascular endpoints in the hypertensive population.
Given that global statistics indicate that there are currently around 6 million hypertension-related deaths per year and that cardiovascular disease will become the number one cause of death by the year 2020, and that hypertension is a major contributing risk factor, it is clearly of vital importance that we ascertain the optimal treatment strategies to prevent hypertension-related cardiovascular disease.
There are a number of key issues to address before we look at the current meta-analyses.
First, antihypertensive therapy has been convincingly shown to reduce stroke incidence. 2 Individual trials and earlier meta-analyses suggest that the reduction in stroke incidence observed in the trials is similar to that predicted from prospective observational studies for a similar average fall in BP (5-6 mmHg diastolic BP) over a period of about five years. 2, 3 Although encouraging, this is perhaps surprising in that it suggests complete reversal of the BP-related cerebrovascular risk by antihypertensive drugs, over this range of diastolic pressure. It is possible, however, that the slope of the BP-risk relationship in some hypertensive groups may be steeper, in which case there may be potential for greater protection against stroke with alternative therapeutic strategies.
Early trials failed to demonstrate that antihypertensive therapy protected against MI. [4] [5] [6] These trials were clearly underpowered to address this question and meta-analyses 2 of pooled data suggested some protection (about 16% relative risk (RR) reduction) against a predicted reduction of 20-25% from prospective observational studies for the same reduction in BP.
Given that these early trials and meta-analyses were based on treatment regimens comprising diuretics and beta-blockers, to which an assortment of sympatholytic and vasodilator drugs were variously added,how would the 'newer'classes of agents compare? Regrettably, there is a paucity of information from placebo-controlled trials with these classes of drugs, at least partly explained by ethical difficulties in defining hypertensive populations in which it is justifiable to conduct placebo-controlled trials.
For the dihydropyridine calcium channel blockers (CCB), clear evidence of benefit was demonstrated with nitrendipine in the Syst.Eur trial, 7 with stroke reduction broadly similar to that seen with older drugs and encouraging reductions in other cardiovascular endpoints.
As discussed in an earlier editorial, 8 there are no placebo-controlled trials reported in hypertensive populations with angiotensin-converting enzyme inhibitors (ACE-I).
Some conclusions will be drawn from the 'HOPE' study with ramipril, 9 where the reduction in stroke incidence and other cardiovascular endpoints was convincing, in a population of patients at high risk of cardiovascular disease. The debate will continue over the proportion of benefit attributed to BP lowering as opposed to drug-or classspecific effects. 10 Clearly, one of the most important questions raised by the early studies is to what extent the CCBs and/or the ACE-I could improve coronary heart disease (CHD) outcome in hypertensive patients, particularly in the light of encouraging data from experimental animal models and their apparent metabolic neutrality compared with older drugs.
It is thus disappointing that unrealistic objectives have formed the rationale for many of the recently reported trials, for example, INSIGHT, 11 STOP-2, 12 NORDIL, 13 CAPPP, 14 in that they were designed with an a priori hypothesis that the 'newer' treatment (CCB or ACE-I) would confer a RR reduction of total cardiovascular events of around 25% compared with older (diuretic-or betablocker-based) treatments. Based on the earlier meta-analyses, the shortfall, in absolute terms, was a 4% difference in CHD (16% observed, 20% expected) and any new trial would have to be powered to detect a difference of 4% in absolute risk, or 20% in RR between the two treatments. None of the aforementioned studies was powered to detect this difference, and the small differences in event rates observed for stroke and CHD could perhaps have been predicted. Hence the need for larger studies. ALLHAT 15 and ASCOT 16 are the only two ongoing studies powered to address this specific question.
The alternative approach is further meta-analyses of smaller studies. The WHO-ISH Blood Pressure Lowering Treatment Trialists Collaboration was established in 1998 and published a protocol for prospective collaborative overviews of major randomised trials of BP-lowering treatments. 17 A registry of trials which satisfied predefined eligibility criteria (randomisation; at least 1000 patient years of follow up per limb; in progress after July 1995) was set up and now includes 37 trials in the register.
The meta-analyses are designed with the objective of comparing the effects of different drug regimens on mortality and major cardiovascular morbidity (stroke, MI, heart failure etc.) which individual trials are underpowered to evaluate.
The results of the first meta-analysis, involving 16 trials and more than 70,000 patients, have recently been published. 1 In those trials which compared different treatments, small differences of marginal significance were observed. For ACE-Ibased treatment, there was no difference in stroke outcome or CHD outcome compared with diureticor beta-blocker-based treatment (RR for stroke 1.05, confidence intervals [CI] 0.92-1.19; RR for CHD 1.00, CI 0.88-1.14).
For CCB-based treatment, the risk of stroke was reduced by 14% (RR 0.86, CI 0.76-0.98), but the risk of CHD was increased by 12% (RR 1.12, CI 1.00-1.26) compared with diuretics. Combining cardiovascular events, there was no overall difference between the treatment regimens.
There are very limited data from studies directly comparing CCB-based regimens with ACE-I-based regimens (ABCD-hypertensive limb, n=470;
18 STOP-2 n=6614). 12 As the authors of the WHO/ISH analysis point out, the marked statistical heterogeneity observed in this particular analysis precludes any definitive statement on differences between ACE-I-and CCBbased treatment on CHD outcome, despite the fact that in STOP-2, CHD events were lower in the ACE-I group (RR 0.82, CI 0.67-1.00).
Two other meta-analyses have also recently been published. 19, 20 In one, the authors have conducted a Medline search for publications including hypertension and outcome, in studies of more than 100 patients. 19 The results of this analysis are broadly similar to those reported by the WHO/ISH collaboration. In a further study, 20 by manipulating the meta-analysis so that CCB-based treatment is compared with diuretic-and beta-blocker-based treatment to which the results of ACE-I-based trials have been added, it is possible to show that the differences in cause-specific outcome (acute MI, heart failure) become greater with CCB-based regimens.
The validity of this type of analysis is, however, open to question, particularly in view of the fact that selection of studies for incorporation into such an analysis in an attempt to favour an a priori hypothesis, must constitute a deviation from objectivity and potentially introduces bias into the analysis.
As He and Whelton point out, 21 these metaanalyses clarify some issues but raise many more. The Blood Pressure Lowering Treatment Trialists Collaboration will conduct further overviews when more data have been made available from ongoing trials. However, whilst this might help clinicians in deciding upon their choice of first line agent, in many patients and, in particular, in the more complex patient, combinations of antihypertensive drug treatments are required to control BP. Only one trial, the ASCOT study, compares CHD outcome with prespecified combinations of antihypertensive drugs, including a combination of a CCB with an ACE-I. This will hopefully address the question of whether a newer regimen including these two classes of agents bears greater benefit than a more traditional combination of a beta-blocker to which a diuretic is added. However, given the expanding number of classes of antihypertensive treatments there is clearly a need for further studies addressing potential benefits or harm from specific combination therapies. 
